Patent SG-11201407803T-A (SG)
Title: Nmr measurements of glyca
Inventor: OTVOS JAMES D
IPC: G01N33/49
Filed: 2013-05-30
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184483 A1 (51) International Patent Classification: G01N24/08 (2006.01) G01N33/49 (2006.01) A61B 5/055 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043343 30 May 2013 (30.05.2013) English (30) Priority Data: 61/657,315 8 June 2012 (08.06.2012) 61/711,471 9 October 2012 (09.10.2012) 61/739,305 19 December 2012 (19.12.2012) 13/830,199 14 March 2013 (14.03.2013) English US US us us (71) Applicant: LIPOSCIENCE, INC. [US/US]; 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (US). (72) Inventors: OTVOS, James D.; 1117 Wellstone Circle, Apex, North Carolina 27502 (US). SHALAUROVA, Ir- ina Y.; 315 Ambermore Place, Cary, North Carolina 27519 (US). BENNETT, Dennis W.; 4242 North Morris Blvd., Shorewood, Wisconsin 53211 (US). WOLAK- DINSMORE, Justyna E.; 2808 Mebane Ln., Durham, North Carolina 27703 (US). (74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, North Carolina 27627 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: NMR MEASUREMENTS OF GLYCA 00 •t •t 00 [Continued on next page] (57) Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure level of a \"GlycA\" in arbitrary units or in defined units (e.g., |imol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra. WO 2013/184483 A11 lllll llllllll II llllll III lllll lllll lllll lllll III III III lllll lllll lllll llll lllllll llll llll llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))